Skip to main content
Premium Trial:

Request an Annual Quote

Flat Q1 Revenues Reported by Epigenomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German molecular diagnostics company Epigenomics today announced flat revenues for the first quarter year over year while its net loss rose 12 percent.

For the three months ended March 31, Epigenomics said that revenues stayed at €621,000 ($888,300), with product sales and commercial R&D activities generating €166,000 and licensing deals generating €455,000.

The firm's R&D costs for the quarter slid 15 percent to €1.6 million from €1.9 million a year ago, while SG&A costs rose 23 percent to €1.6 million from €1.3 million a year ago, as the company prepared to enter the US market.

Epigenomics met with the US Food and Drug Administration in February to discuss its Epi proColon 2.0 test for colorectal cancer, its intended use, and the clinical data needed as part of a submission to the agency. "After this meeting, we still assume to be able to submit an application by the end of the year," the company said.

Epigenomics' net loss for the first quarter was €2.9 million, or € .09 per share, up 12 percent from €2.6 million, or €.07 a share, a year ago.

Epigenomics said that it had cash and cash equivalents of €21.5 million at the end of the quarter.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.